New chimeric RNAs in acute myeloid leukemia

Area of Science:

• Genomics
• Bioinformatics
• Cancer Biology

Background:

• Next-generation sequencing (NGS) and RNA-sequencing (RNA-seq) are crucial for identifying biomarkers in cancer.
• RNA-seq facilitates the understanding of complex diseases and the discovery of novel genetic and transcriptional events.
• Chimeric RNAs (chRNAs) are significant in tumor classification and therapy.

Purpose of the Study:

• To identify and validate novel chimeric RNAs (chRNAs) in acute myeloid leukemia (AML) using RNA-sequencing.
• To analyze the tumor-specific expression of chRNAs in a larger AML cohort.
• To explore the potential of chRNAs as diagnostic and prognostic biomarkers for AML.

Main Methods:

• Utilized Crac, a computational tool for classifying biological events and inferring splice and chimeric junctions from sequencing reads.
• Employed CracTools for aggregating, annotating, and filtering chimeric RNA reads.
• Validated candidate chRNAs using real-time PCR and sequencing, and analyzed tumor-specific expression in a public RNA-seq dataset.

Main Results:

• Identified and validated 17 chimeric RNAs (chRNAs) across 3 acute myeloid leukemia (AML) patients with varying chromosomal abnormalities.
• Classified the novel fusion transcripts into four distinct groups based on exon organization.
• Observed complex and distinct synthesis mechanisms for the identified chRNAs.

Conclusions:

• The identified chRNAs suggest diverse mechanisms of formation involving collinear, non-collinear, or inter-chromosomal exons.
• Tumor-specific expression analysis in a larger AML cohort revealed potential new biomarkers.
• These novel chRNAs could enhance the diagnostic and prognostic capabilities for acute myeloid leukemia.